CAJ | 학술논문

目的：观察依帕司他联合甲钴胺治疗糖尿病周围神经病变的疗效。方法将80例患者随机分为治疗组和对照组，各40例。在治疗糖尿病的同时，治疗组加用依帕司他50 mg 口服、每日3次，甲钴胺500μg 口服、每日3次；对照组予甲钴胺500μg 口服，每日3次。均以12周为1个疗程。结果治疗组总有效率为92.50%，明显高于对照组的72.50%( P <0.05)，两组神经传导速度差异有统计学意义( P <0.01)，未出现明显不良反应。结论依帕司他联合甲钴胺治疗糖尿病周围神经病变疗效确切。
목적：관찰의파사타연합갑고알치료당뇨병주위신경병변적료효。방법장80례환자수궤분위치료조화대조조，각40례。재치료당뇨병적동시，치료조가용의파사타50 mg 구복、매일3차，갑고알500μg 구복、매일3차；대조조여갑고알500μg 구복，매일3차。균이12주위1개료정。결과치료조총유효솔위92.50%，명현고우대조조적72.50%( P <0.05)，량조신경전도속도차이유통계학의의( P <0.01)，미출현명현불량반응。결론의파사타연합갑고알치료당뇨병주위신경병변료효학절。
Objective To evaluate the clinical efficacy of epalrestat and Methycobal combined therapy in treating diabetic peripheral neuropathy(DPN) . Methods 80 cases of peripheral neuropathy and type 2 diabetes were randomly separated into an experiment group and a control group, 40 cases of each group. The normal treatment of diabetes was used in two groups, members in the experiment group were treated with methycobal 500 μg, 3 times one day. and epalrestat 50 mg, 3 times one day; members in the control group were treat-ed with methycobal 500 μg, 3 times one day. At the end of 12 weeks, therapeutic courses, motor nerve conduction velocity (MNCV) and sural nerve conduction velocity(SNCV) were evaluated. Results The overall effective rate was 92. 50% in the experiment group and 72. 50% in the control group, showing significant different between the two groups( P < 0. 05) . The post therapeutic values of both SNCV and MNCV were significantly difference from those of previous treatment( P < 0. 01 ) . No evidently relative adverse effects were observed in both groups. Conclusion Combined therapy of epalrestat and Methycobal was more effective in controlling the clinical ac-tivity to diabetic peripheral neuropathy.